Information for Health Professionals

The following section contains in-depth information about the scientific and clinical trials undertaken.

Scientific & Clinical Trials | Patents

Acid Reflux or Gastro-Oesophageal Reflux (GOR) is a condition suffered by many individuals at some point in their lives, with some estimates suggesting 60-70% of the population suffering from reflux in any 12-month period. A more severe and chronic progression is diagnosed as Gastro-Oesophageal Reflux Disease (GORD; also known as GERD) approximately 60,000 people are hospitalised with severe GORD a year in Australia alone.

The diagnosis of GORD is generally set by its cardinal symptoms of heartburn and acid regurgitation, occurring at least weekly. The prevalence of these weekly symptomatic events among adults has been reported to be in the range of 10-20% in the western world, with higher prevalence in recent years. A study ranging over the last 10 years including 80,000 subjects revealed an increase of 47% on weekly events with gender and age being significant factors.

  • KFSU holds and is presently at the national application phase of a patent for the treatment of acid reflux and gastro-oesophageal reflux disease in the EU, Japan and Australia and has been granted a full patent in the US after final examination.
  • The prebiotic phytonutrient fibre extract from sugarcane has an anecdotal record of amelioration of symptoms for both chronic and acute acid reflux/indigestion.
  • A lifestyle study recording beneficial effects and a human clinical trial study are currently underway to demonstrate the high efficacy of Kfibre for providing relief of reflux symptoms. Patented treatment formats cover both functional foods and pharmaceutical approaches.


Patent Application “Dietary Supplement for the treatment of acid reflux and gastro-oesophageal reflux disease (GORD/GERD)”

According to an aspect of the invention, there is provided a method of treatment of the chronic and acute effects of Acid reflux or GORD/GERD over an extended period in an individual by feeding to said individual a food product incorporating dietary fibre material extracted from sugar cane.

Clinical Trials – Planning phase for therapeutic evidence

In order to test an alternative GORD/GERD treatment, a clinical trial is currently being conducted using Kfibre compared to a placebo of insoluble crystalline cellulose fibre. The study is being conducted in Launceston by doctors in association with gastric clinics. Results expected Dec 2018.

If you’re a health professional and would like more information or a discussion on the above, please contact us.

Inflammatory Bowel Disease (IBD) is the collective condition label given to a number of gastrointestinal (GI) disorders that result in colitis of the GI tract, or chronic gut inflammation. IBD is now considered an emerging global disease with increasing prevalence, severity and complexity especially in western societies. The baseline treatment and avoidance of inflammatory events can be approached from a dietary perspective and studies demonstrate a role for prebiotics, probiotics and the synergistic combination administration, labelled synbiotics.

A unique prebiotic phytonutrient fibre extract from sugarcane, manufactured to preserve the cell wall components provides a more representative cellular fibre component from plant dietary sources. These components target the normalisation of gut microbiota, the production of beneficial by-products of microbial digestion (such as short chain fatty acids), the delivery of plant antioxidants to the colon, and when supplying a known beneficial probiotic, the synergistic effects result in an amplification of the measurable benefits.
KFSU‘s University research partner holds a provisional patent for the prophylaxis and treatment of Inflammatory Bowel Disease using sugarcane cellular complex, and KFSU has exclusive global rights for commercialization.

  • Evidence supporting the patent comes from a scientific animal trial whereby sugarcane fibre, as both a stand-alone treatment, and as a synbiotic (combination of Kfibre and a probiotic bacterial strain), significantly reduced or prevented gut inflammation (colitis).

This research continues with exciting information to release when the University has completed and published the next phase. We aim to take this to human efficacy trials to confirm the anecdotal testimonials and outcomes.

Provisional Patent Application

  • The invention relates to the field of food supplement manufacture and therapeutic manufacture. In particular, the invention relates to use of a prebiotic whole plant fibre extract from sugarcane in the diet of an individual for the prophylaxis and/or treatment of Inflammatory Bowel Disease.
  • The invention also relates to a combination of the prebiotic whole plant fibre extract from sugarcane and probiotic strains, the synbiotic use of said combination in the diet of an individual, and the improved outcomes of the synbiotic approach in the prophylaxis and/or treatment of Inflammatory Bowel Disease.

Clinical Trials – trial underway for therapeutic evidence

Human clinical trials are in the planning phase based on the strong results of the animal study.

If you’re a health professional and would like more information or a discussion on the above, please contact us.

Ready to change your Gut Health?

Order Now